Gritstone bio announced that it has commenced an underwritten public offering of shares of its common stock and accompanying common warrants to purchase common stock . All of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by Gritstone bio. TD Cowen and Evercore ISI are acting as the joint book-running managers for the proposed offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRTS:
- Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
- Gritstone reduced workforce by 40% in February
- Gritstone reports FY23 EPS ($1.20) vs ($1.32) last year
- Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Gritstone Oncology (GRTS) Q4 Earnings Cheat Sheet
